In order to develop new therapeutic agents one must first identify a potential target; Information on the function of such a target and differences between tumour and normal cell behaviour are instrumental in determining whether the chosen target will prove to be viable. How tumour cells interact with their environment plays a crucial part in tumour cell biology, and our increasing knowledge on how cells can integrate signals that regulate cell cycle information and apoptosis, on one hand, or migration and invasion, on the other, will help the development of new strategies. A number of speakers addressed this issue. For example, the GI phase of the cell cycle is jointly regulated by mitogenic growth factors and the extracellular matrix (ECM) (Assoian, Miami). This joint regulation was shown to be a co-ordinated effect of growth factors and the ECM on the GI phase cyclin-dependent kinases. Assoian provided evidence for both integrated pathways and parallel, independent pathways from growth factors and ECM signals.
MOLECULAR MEDICINE
Using genetic and cellular information to generate new therapies for cancer is a major challenge. Indeed, a criticism of much cancer research is that there is little point in finding the cause of the disease if this information offers no hope for disease prevention or treatment. However, the turning point has arrived and, as we progress towards the 21st century, the past 40 years of conventional cancer therapies are becoming augmented by a new generation of innovative molecular therapeutics founded on (Assoian, Miami) . This joint regulation was shown to be a co-ordinated effect of growth factors and the ECM on the GI phase cyclin-dependent kinases. Assoian provided evidence for both integrated pathways and parallel, independent pathways from growth factors and ECM signals.
Focal adhesions are sites where clustered integrins provide adhesion on the outside to the ECM and attachment to the actin cytoskeleton at their cytoplasmic face. Their formation is under the control of the small G protein Rho. Rho appears to promote assembly of focal adhesions by initiating several synergistic pathways, and Burridge (Chapel Hill) presented data supportive of a role for Rho in the stimulation of myosin filament assembly. The resultant contractility of the cells exerts tension on the integrins, clustering them at points of ECM contact and initiating focal adhesion assembly. The regulation of focal adhesion turnover plays a key role in cell motility, and it is of interest that Tiaml, an activator of Rac, which is a Rho family member, was identified as a gene involved in invasion and metastasis (van Leeuwen, Amsterdam) . Their data suggest that the signalling pathways controlled by Rac and Rho, which participate in the co-ordination of cell movement, play an important role in tumour invasion and metastasis. kinases. A number of approaches to inhibit Ras function are possible, such as inhibition of farnesyl transferase processing of Ras proteins, blocking GTP binding and inhibition of signalling through Ras pathways. Increased knowledge of the Ras signalling pathway has identified key candidates for development of the latter approach (such as Raf and MAP kinase) and Marshall outlined two methods for screening inhibitors of the Ras pathway that are being undertaken. Firstly, automated in vitro enzyme screens using recombinant Raf and MAP kinase and, secondly, use of yeast expressing the mammalian genes for Raf and MAP kinase as an in vivo screen using the mating response transcription activation as a read out.
Mutations in the tumour-suppressorp53 are the most commonly found genetic alterations in human cancers, and Lane (Dundee) presented his approach to restore p53 function in tumours. mdm2 is an oncogene that is amplified/overexpressed in a variety of solid tumours in which wild-type p53 is present and it prevents p53 function. They have developed peptides that mimic the binding site for mdm2 and can displace mdm2 from p53 in vitro. In cells, the problem with handling peptides has been overcome by the use of thioredoxin-insert proteins (TIPs) in which the peptide sequences are inserted into the thioredoxin/active site and transported into the cells. Thus an agent has been developed that targets mdm2-p53 interactions and mimics conventional therapeutics without causing DNA damage to activate p53.
Another example of how disruption of protein-protein interactions may lead to a therapeutic agent came from studies on the regulation of the transcription factor E2F. In this case, peptides that block the formation of E2F-DP-1 heterodimers, which regulate the G1/S phase transition, cause apoptosis in tumour cells (La Thangue, Glasgow) . Other aspects of cell cycle regulation discussed were the regulation of D type cyclins. The elegant in vitro analysis of cyclin D phosphorylation (Sherr, Memphis) pointed out possible future targets for molecules able to modulate the phosphorylation of such key regulatory molecules. It is clear that a number of different approaches are being developed for the generation of new therapeutic agents, however one important point was highlighted by Bartek (Copenhagen). In cancer cells, there are aberrations in a few key regulatory pathways, for example restriction point control, genome integrity control, cell death pathways, cell-cell matrix interactions, and it may be necessary to target more than one regulatory pathway to achieve a therapeutic effect. In human carcinoma cells, overexpression of p53 and the cell cycle regulator p16, but not p53 on its own, induced apoptotic cell death in tumours, which Bartek believes could be the basis for the development of a new strategy for cancer gene therapy. This theme was continued by Land (London) who addressed the question of oncogene co-operation, when dominant negative p53 and Myc co-operate with Raf via distinct mechanisms, although the two pathways converge on the regulation of cyclin/cdk activities.
Another potential therapeutic approach discussed was the introduction of the adenovirus Ela protein, as a master programmer of the epithelial phenotype, into tumour cells (Frisch, La Jolla) . This renders the tumour cells sensitive to anoikis, anchorage dependent and non-tumorigenic. Frisch is currently exploring the therapeutic potential of this seemingly broad-range tumour-suppressor protein.
A number of clinical studies were described in which novel approaches to therapy have been used based on an increased knowledge of the genetics and biology of the diseases. Ganly (Glasgow) described a phase 1 trial that is under way using an Beatson Intemational Cancer Conference 1717 adenovirus targeted to mutant p53 in patients with squamous cell carcinoma of the head and neck. In this disease, more than 80% of recurrent tumours have p53 mutations. To date, 27 patients have entered the trial and have experienced limited toxicities. Although no complete or partial responses to the complete tumour burden were seen, necrosis and regression of the injected tumours were observed and a multicentre phase 2 trial is planned.
BRCAI A PARADIGM FOR CANCER THERAPY?
Returning to the major theme of the meeting, there can be no better example of a field of study that encompasses 'Cancer: from Pedigree to Protein', than BRCAJ. Having discussed pedigree studies and the relevance of specific mutations (Peto, Surrey), we were treated to lively debate on the function and cellular location of the BRCA1 protein (Holt, Nashville; Sherr, Memphis; Black, Glasgow). As to a consensus of opinion on this, there was none! Yet despite the incomplete information on BRCA1 function, Holt (Nashville) presented some very impressive clinical studies on the successful use of retroviral gene transfer of BRCAJ in ovarian cancer. Thus, although the mechanism of treatment may not be completely understood at present, the parallel progress of the laboratory based and clinical studies has certainly provided optimism for new molecular therapies.
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